These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36201220)

  • 21. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
    Walpole I; Lee B; Shapiro J; Thomson B; Lipton L; Ananda S; Usatoff V; Mclachlan SA; Knowles B; Fox A; Wong R; Cooray P; Burge M; Clarke K; Pattison S; Nikfarjam M; Tebbutt N; Harris M; Nagrial A; Zielinski R; Chee CE; Gibbs P
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):214-225. PubMed ID: 35831999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in patients with pancreatic ductal adenocarcinoma with neoadjuvant treatment and pancreatectomy.
    Kawada T
    J Surg Oncol; 2022 May; 125(6):1071. PubMed ID: 35267194
    [No Abstract]   [Full Text] [Related]  

  • 26. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
    Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
    Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.
    Kalimuthu SN; Serra S; Dhani N; Chetty R
    J Clin Pathol; 2016 Jun; 69(6):463-71. PubMed ID: 26915370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
    Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
    J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned.
    Henault D; Westphalen CB; O'Kane GM
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):186-188. PubMed ID: 38237623
    [No Abstract]   [Full Text] [Related]  

  • 36. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Hashimoto D; Yamamoto T; Yamaki S; Hirooka S; Ishida M; Ikeura T; Inoue K; Sekimoto M
    J Hepatobiliary Pancreat Sci; 2022 Feb; 29(2):262-270. PubMed ID: 34314568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
    Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence.
    Brown ZJ; Ruff SM; Cloyd JM
    Curr Opin Pharmacol; 2022 Dec; 67():102305. PubMed ID: 36223686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
    Chen Q; Cui SP; Wang D; Lang R
    Asian J Surg; 2023 Apr; 46(4):1824-1825. PubMed ID: 36369134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.